Raed Al-Rajabi, MD
University of Kansas Medical Center
1
1
0
N/A
0
0
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (1)
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Li-Yuan Bai, MD,PhD
China Medical University Hospital
Shared therapeutic areas:
Ghassan Abou-Alfa, MD
Memorial Sloan Kettering Cancer Center
Shared therapeutic areas:
Tsang-Wu Liu, MD
Taiwan Cooperative Oncology Group, National Health Research Institutes
Shared therapeutic areas:
Midhun Malla, MD, MS
University of Alabama at Birmingham
Shared therapeutic areas:
Eric K Rowinsky, MD
Uniphar Development, LLC
Shared therapeutic areas:
Chen Ming-Huang, MD
Taipei Veterans General Hospital, Taipei, TAIWAN
Shared therapeutic areas:
Ming Kuang, PhD
First Affiliated Hospital, Sun Yat-Sen University
Shared therapeutic areas:
Vaibhav Sahai, MBBS, MS
University of Michigan
Shared therapeutic areas:
Benjamin Weinberg, MD
Georgetown University
Shared therapeutic areas:
Peng Wang, MD
Fudan University Shanghai Cancer Center, Shanghai
Shared therapeutic areas:
Publications (0)
No publications found for this investigator.
Clinical Trials (1)
Showing 1 of 1 trials
The Purpose of This Trial is to Determine if Regorafenib Plus Durvalumab (MEDI4736) is Safe and Effective in Treatment of Chemo Refractory Advanced Biliary Tract Cancers
All 1 trials loaded